Pfizer Inc. (NYSE:PFE) Shares Bought by JTC Employer Solutions Trustee Ltd

JTC Employer Solutions Trustee Ltd grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 400.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,000 shares of the biopharmaceutical company’s stock after purchasing an additional 12,000 shares during the period. JTC Employer Solutions Trustee Ltd’s holdings in Pfizer were worth $416,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. KFG Wealth Management LLC bought a new position in Pfizer during the 1st quarter valued at $609,000. Caldwell Sutter Capital Inc. boosted its stake in Pfizer by 2.3% during the first quarter. Caldwell Sutter Capital Inc. now owns 73,621 shares of the biopharmaceutical company’s stock valued at $2,043,000 after buying an additional 1,674 shares in the last quarter. Denali Advisors LLC grew its holdings in Pfizer by 11.9% during the first quarter. Denali Advisors LLC now owns 29,200 shares of the biopharmaceutical company’s stock worth $810,000 after acquiring an additional 3,100 shares during the period. Carret Asset Management LLC raised its position in Pfizer by 10.4% in the first quarter. Carret Asset Management LLC now owns 122,917 shares of the biopharmaceutical company’s stock worth $3,411,000 after acquiring an additional 11,577 shares in the last quarter. Finally, Tradewinds Capital Management LLC lifted its holdings in Pfizer by 27.3% in the 1st quarter. Tradewinds Capital Management LLC now owns 2,330 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 500 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 0.6 %

Shares of PFE stock traded down $0.16 during trading on Wednesday, hitting $27.67. 15,180,087 shares of the company were exchanged, compared to its average volume of 40,441,617. The business’s 50-day simple moving average is $27.96 and its 200 day simple moving average is $27.71. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $37.80. The firm has a market capitalization of $156.79 billion, a price-to-earnings ratio of -462.33, a P/E/G ratio of 1.10 and a beta of 0.69. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the prior year, the firm earned $1.23 EPS. The company’s revenue was down 19.5% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.07%. The ex-dividend date is Thursday, July 25th. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Morgan Stanley boosted their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday, June 26th. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Nine investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $35.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.